ArticleLifetime data analysis2025
Causal effect estimation on restricted mean survival time under case-cohort design via propensity score stratification.
Article in Lifetime data analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In large observational studies with survival outcome and low event rates, the case-cohort design is commonly used to reduce the cost associated with covariate measurement. The restricted mean survival time (RMST) difference has been increasingly used as an alternative to hazard ratio when estimating the causal effect on survival outcomes. We investigate the estimation of marginal causal effect on RMST under the stratified case-cohort design while adjusting for measured confounders through propensity score stratification. The asymptotic normality of the estimator is established, and its variance formula is derived. Simulation studies are performed to evaluate the finite sample performance of the proposed method compared to several alternative methods. Finally, we apply the proposed method to the Atherosclerosis Risk in Communities study to estimate the marginal causal effect of high-sensitivity C-reactive protein level on coronary heart disease-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.